IBIO Quote, Financials, Valuation and Earnings

Minerva Neurosciences, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of --. iBio, Inc.'s return on equity of -88.23% beat Minerva Neurosciences, Inc.'s return on equity of --.

iBio, Inc. has a consensus price target of $4.77, signalling upside risk potential of 178.75%. On the other hand Minerva Neurosciences, Inc. has an analysts' consensus of $4.50 which suggests that it could grow by 10.84%. Given that iBio, Inc. has higher upside potential than Minerva Neurosciences, Inc., analysts believe iBio, Inc. is more attractive than Minerva Neurosciences, Inc..

iBio, Inc. has a beta of 1.135, which suggesting that the stock is 13.459% more volatile than S&P 500. In comparison Minerva Neurosciences, Inc. has a beta of -0.396, suggesting its less volatile than the S&P 500 by 139.575%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Minerva Neurosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Minerva Neurosciences, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are $100K, which are larger than Minerva Neurosciences, Inc. quarterly revenues of --. iBio, Inc.'s net income of -$5.7M is lower than Minerva Neurosciences, Inc.'s net income of -$2.7M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Minerva Neurosciences, Inc.'s PE ratio is 2.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 75.58x versus -- for Minerva Neurosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of -3135.32%. iBio, Inc.'s return on equity of -88.23% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

iBio, Inc. has a consensus price target of $4.77, signalling upside risk potential of 178.75%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 70.32%. Given that iBio, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe iBio, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

iBio, Inc. has a beta of 1.135, which suggesting that the stock is 13.459% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are $100K, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. iBio, Inc.'s net income of -$5.7M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 75.58x versus 37.70x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Senti Biosciences, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of --. iBio, Inc.'s return on equity of -88.23% beat Senti Biosciences, Inc.'s return on equity of -173.17%.

iBio, Inc. has a consensus price target of $4.77, signalling upside risk potential of 178.75%. On the other hand Senti Biosciences, Inc. has an analysts' consensus of $11.50 which suggests that it could grow by 995.24%. Given that Senti Biosciences, Inc. has higher upside potential than iBio, Inc., analysts believe Senti Biosciences, Inc. is more attractive than iBio, Inc..

iBio, Inc. has a beta of 1.135, which suggesting that the stock is 13.459% more volatile than S&P 500. In comparison Senti Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Senti Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Senti Biosciences, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are $100K, which are larger than Senti Biosciences, Inc. quarterly revenues of --. iBio, Inc.'s net income of -$5.7M is higher than Senti Biosciences, Inc.'s net income of -$18.1M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Senti Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 75.58x versus 3.27x for Senti Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vor Biopharma, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of --. iBio, Inc.'s return on equity of -88.23% beat Vor Biopharma, Inc.'s return on equity of --.

iBio, Inc. has a consensus price target of $4.77, signalling upside risk potential of 178.75%. On the other hand Vor Biopharma, Inc. has an analysts' consensus of $43.25 which suggests that it could grow by 245.17%. Given that Vor Biopharma, Inc. has higher upside potential than iBio, Inc., analysts believe Vor Biopharma, Inc. is more attractive than iBio, Inc..

iBio, Inc. has a beta of 1.135, which suggesting that the stock is 13.459% more volatile than S&P 500. In comparison Vor Biopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vor Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Vor Biopharma, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are $100K, which are larger than Vor Biopharma, Inc. quarterly revenues of --. iBio, Inc.'s net income of -$5.7M is higher than Vor Biopharma, Inc.'s net income of -$812.7M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Vor Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 75.58x versus -- for Vor Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.